BIGBEAR Pharmaceutical announces the approval of Selumetinib in Laos

Date:2024-07-02 Views: 49 Times

Vientiane, Laos - April 8, 2024 - BigBear Pharma, a leading biopharmaceutical company focused on developing and commercializing innovative cancer treatments, today announced that 2 products have been approved by the Ministry of Health of Laos.

Approved drugs are:

Selumetinib: sold under the brand name SEMEDX.

  • Lao registered trade name: Lao Reg No.: 03L1085/24
  • Lao registered trade name: Lao Reg No.: 04L1095/24

Selumetinib was approved for marketing in the United States on April 10, 2020. It is suitable for children aged 2 years and above with neurofibromatosis type 1 (NF1) to treat inoperable plexiform neurofibromas (PN). patient. Selumetinib is a kinase inhibitor (TKI) targeting MEK, a key protein kinase in the RAS/MAPK signaling pathway. Selumetinib can selectively inhibit MEK1 and MEK2, thereby normalizing dysregulated signaling pathways.

About BigBear Pharmaceuticals:

BigBear Pharmaceuticals is headquartered in Vientiane, the capital of Laos. The company is committed to drug research and development, production and sales, providing high-quality, safe and effective pharmaceutical products. BigBear Pharmaceuticals has established a good reputation in the Lao drug market with its excellent professional knowledge and innovation capabilities, and actively participates in international pharmaceutical cooperation and exchanges.

Forward-Looking Statements:

Within the scope of applicable laws and regulations, "plans," "goals," "expectations," "forecasts" and other similar expressions appearing in this press release are forward-looking statements. The forward-looking statements set forth herein involve a number of risks and uncertainties that could differ materially from actual results. Important factors leading to such differences include, but are not limited to, changes in regulatory and/or economic conditions, uncertainties in clinical study results, exposure to various market risks and other factors beyond the Company's control.

Retrieved July 01,2024, From